Omnicell, Inc. (NASDAQ:OMCL) Stake Increased by Royce & Associates LP

Royce & Associates LP increased its stake in Omnicell, Inc. (NASDAQ:OMCL) by 4.4% in the fourth quarter, Holdings Channel reports. The institutional investor owned 19,417 shares of the company’s stock after acquiring an additional 820 shares during the quarter. Royce & Associates LP’s holdings in Omnicell were worth $864,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Victory Capital Management Inc. increased its stake in shares of Omnicell by 32.9% in the fourth quarter. Victory Capital Management Inc. now owns 1,526,309 shares of the company’s stock worth $67,951,000 after buying an additional 377,883 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. increased its stake in shares of Omnicell by 93.3% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,450,416 shares of the company’s stock worth $64,573,000 after buying an additional 699,925 shares during the last quarter. ArrowMark Colorado Holdings LLC increased its stake in shares of Omnicell by 27.1% in the third quarter. ArrowMark Colorado Holdings LLC now owns 1,140,873 shares of the company’s stock worth $49,742,000 after buying an additional 243,353 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Omnicell by 0.3% in the third quarter. Geode Capital Management LLC now owns 1,104,745 shares of the company’s stock worth $48,176,000 after buying an additional 2,877 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Omnicell by 3.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 616,153 shares of the company’s stock worth $27,431,000 after purchasing an additional 21,157 shares during the period. Institutional investors own 97.70% of the company’s stock.

Omnicell Stock Performance

Shares of OMCL opened at $33.94 on Friday. Omnicell, Inc. has a 1 year low of $25.12 and a 1 year high of $55.75. The company has a market cap of $1.59 billion, a price-to-earnings ratio of 125.71, a price-to-earnings-growth ratio of 7.53 and a beta of 0.85. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37. The firm has a fifty day moving average of $39.77 and a 200-day moving average of $42.91.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. As a group, equities analysts anticipate that Omnicell, Inc. will post 1.09 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on OMCL shares. StockNews.com raised shares of Omnicell from a “hold” rating to a “buy” rating in a report on Thursday, March 6th. JPMorgan Chase & Co. decreased their price objective on shares of Omnicell from $44.00 to $36.00 and set a “neutral” rating for the company in a report on Thursday. Bank of America decreased their price objective on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a report on Monday, January 6th. Benchmark reaffirmed a “buy” rating and issued a $62.00 price objective on shares of Omnicell in a report on Tuesday, February 4th. Finally, Wells Fargo & Company decreased their price objective on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $51.00.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.